Investing
Monday's Top Analyst Upgrades and Downgrades: Foot Locker, Halozyme Therapeutics, Kimberly-Clark, Occidental Petroleum, Texas Roadhouse, Trip.com and more
May 17, 2021 8:50 am
Last Updated: August 10, 2021 2:32 pm
BRF S.A. (NYSE: BRFS): Barclays downgraded it to Underweight from Equal Weight. The stock has traded in a 52-week range of $2.85 to $4.84 and has a $5.36 consensus price target. The shares closed Friday at $3.99.
Decker’s Outdoors Corp. (NASDAQ: DECK): Telsey Advisory raised the price target on the shares to $375 from $355, after the company posted impressive fiscal third-quarter results. The consensus price objective is up at $390.75, and Friday’s final trade was reported at $335.75, after almost a 4% gain for the day.
DoubleVerify Holdings Inc. (NYSE: DV): This company had a recent initial public offering, and Goldman Sachs started coverage with a Buy rating and a $47 price target. JPMorgan has an Outperform rating with a $40 target. Needham checks in with a Buy rating and a $41 price objective, and Canaccord Genuity’s Buy rating comes with a $40 target. The stock closed trading on Friday at $30.86.
Foot Locker Inc. (NYSE: FL): Telsey Advisory raised its $56 price target on the popular shoe retailer to $60. The consensus target is $59.17, but the stock closed above both levels at $64.60 on Friday.
Halozyme Therapeutics Inc. (NASDAQ: HALO): SVB Leerink started coverage at Outperform with a $56 price target. That compares with the lower consensus target of $49.40 and Friday’s closing print of $43.03.
Kimberly-Clark Corp. (NYSE: KMB): Zacks selected this as its Bear of the Day, suggesting that the pandemic boost looks to be over for this consumer staples giant. Shares last closed at $ 134.18, and the consensus price target is $141.81.
Lion Electric Co. (NYSE: LEV): National Bank Financial started covering the stock with an Outperform rating and a $20 price target. No consensus target was available, and the shares popped almost 8% in Friday’s session to close at $15.09.
Mirati Therapeutics Inc. (NASDAQ: MRTX): Oppenheimer’s downgrade was to Perform from Outperform. The stock has traded in a wide 52-week range of $91.90 to $249.42, and it has a consensus price objective of $237.22. The last trade for Friday came in at $156.62.
NeuroPace Inc. (NASDAQ: NPCE): SVB Leerink started coverage with an Outperform rating and a $25 price target. No consensus price objective was available. The stock closed on Friday at $20.91.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.